RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentaries:

Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times

IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News

Commentary from the author on Twitter (thread – click for more)

Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV

— Sumanta Pal (@montypal) September 10, 2022